These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Clinical effects of topical pimecrolimus in a patient with Fox-Fordyce disease. Milcic D; Nikolic M Australas J Dermatol; 2012 May; 53(2):e34-5. PubMed ID: 22571582 [TBL] [Abstract][Full Text] [Related]
45. [A case for diagnosis: Fox-Fordyce disease]. Kourda M; Hamza S; Battikh O; Bouteraa A; Souissi R Ann Dermatol Venereol; 1997; 124(8):561-2. PubMed ID: 9740855 [No Abstract] [Full Text] [Related]
46. Pathophysiology, clinical findings, and management of Fox-Fordyce disease: A systematic review. Salloum A; Bouferraa Y; Bazzi N; Bou Zerdan M; Abi Chebl J; Chu T; Bachour J; Benedetto A J Cosmet Dermatol; 2022 Feb; 21(2):482-500. PubMed ID: 33817950 [TBL] [Abstract][Full Text] [Related]
47. [Axillary and perimamillary Fox-Fordyce disease (apocrine miliaria) in a 19-year-old woman]. Hanner S; Schneiderbauer R; Enk A; Toberer F Hautarzt; 2018 Apr; 69(4):313-315. PubMed ID: 29110043 [TBL] [Abstract][Full Text] [Related]
48. Histopathology attributes of Fox-Fordyce disease. Brau Javier CN; Morales A; Sanchez JL Int J Dermatol; 2012 Nov; 51(11):1313-8. PubMed ID: 23067079 [TBL] [Abstract][Full Text] [Related]
49. FOX-FORDYCE DISEASE: TREATMENT WITH AN ORAL CONTRACEPTIVE. KRONTHAL HL; POMERANZ JR; SITOMER G Arch Dermatol; 1965 Mar; 91():243-5. PubMed ID: 14246163 [No Abstract] [Full Text] [Related]